Description

Madrigal’s $12B Puzzle: Is The Takeover Already Priced In?

Takeover chatter can move a stock quickly, but the more important question is whether the market is reacting to rumor or to a business that has already crossed into a different category of value creation. Madrigal Pharmaceuticals now sits in that exact debate. Shares jumped on renewed acquisition speculation, yet the company’s latest operating update shows this is no longer a story built only on possibility. Rezdiffra ended 2025 at nearly $1 billion in net sales, patient adds continued through year-end, and management described the drug as the foundational therapy in MASH while outlining a pipeline that now extends beyond a single-product launch story. That changes the framing materially. The central issue is not whether Madrigal has become strategically interesting; the earnings call makes that point more clearly than rumor ever could.